Protocol Ledger

NCT05882357 · Phase III · COMPLETED

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Interventional Phase III clinical trial protocol NCT05882357 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-27 Enrollment: 67 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05882357
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)67 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05882357
Protocol FieldVerified Registry Value
NCT IdentifierNCT05882357
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment67 participants (ACTUAL)
Registered Start Date2023-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05882357
Hospital Research SiteLocationSite Profile
Queensland Children's HospitalSouth Brisbane, AustraliaOpen Hospital Dossier ->
The Children's Hospital at WestmeadWestmead, AustraliaOpen Hospital Dossier ->
The Hospital for Sick ChildrenToronto, CanadaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI